Сравнение

Icatibant vs. Plecanatid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

138614-30-9

467426-54-6

Молекулярная масса

1304.52 g/mol

1682 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Plecanatid

Plecanatide is structurally analogous to the body's own uroguanylin and, like it, activates the GC-C receptor at the gut surface, raising cGMP and fluid secretion. Its pH-dependent activity shifts the effect toward the proximal small intestine.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Icatibant	Plecanatid
Германия	Рецептурный	Не одобрено
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Icatibant and Plecanatid?: Icatibant is classified as "Исследования (прочее)", while Plecanatid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Plecanatid?: The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Plecanatid in Germany and the United States?: Германия: Icatibant — Рецептурный, Plecanatid — Не одобрено. США: Icatibant — Рецептурный, Plecanatid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Plecanatid

Германия

Рецептурный

Не одобрено

США

Рецептурный

Frequently asked questions

What is the difference between Icatibant and Plecanatid?

Icatibant is classified as "Исследования (прочее)", while Plecanatid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Plecanatid?

The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Plecanatid in Germany and the United States?

Германия: Icatibant — Рецептурный, Plecanatid — Не одобрено. США: Icatibant — Рецептурный, Plecanatid — Рецептурный. These are factual summaries with source and review date on the individual pages.